Morbidity and Mortality Associated with COVID-19 and Acute Chest Syndrome in Sickle Cell Disease Patients
Fiche du document
22 juillet 2024
- ISIDORE Id: 10670/1.323cad...
- hal: hal-04807362
- doi: 10.1080/03630269.2024.2378069
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1080/03630269.2024.2378069
info:eu-repo/semantics/OpenAccess
Mots-clés
Sickle cell disease acute chest syndrome CoViD-19 prognostic factors morbidity mortality Sickle cell disease acute chest syndrome CoViD-19 prognostic factors morbidity mortality Sickle cell disease Acute Chest Syndrome COVID-19 prognostic factors Acute Chest Syndrome COVID-19Sujets proches
Patients--Mortality Sickle cell disease Meniscocytosis Drepanocytic anemia Mortality, Law of Factors Agents, Manufacturers' Manufacturers' representatives Sickness Human beings--Diseases Morbidity Illness Sicknesses Illnesses Factors Thorax, HumanCiter ce document
Mohamed Keita et al., « Morbidity and Mortality Associated with COVID-19 and Acute Chest Syndrome in Sickle Cell Disease Patients », HAL SHS (Sciences de l’Homme et de la Société), ID : 10.1080/03630269.2024.2378069
Métriques
Partage / Export
Résumé
cOViD-19 infection has emerged as a comorbidity that can significantly increase morbidity and mortality in sickle cell patients with acs (acute thoracic/chest syndrome). the aim of our study was to assess cOViD-19-related morbidity and mortality in sickle cell patients with acs. this was a retrospective, descriptive study of patient records followed over a 36-month period from January 2020 to December 2022. the study was conducted at the national blood transfusion center in Dakar. the sex ratio (M/F) was 0.82. the median age was 26 (17-39) years. the most represented age group was between 21 and 30 years. Factors associated with death were: at baseline, ss genotype, presence of comorbidities (asthma, chronic obstructive pulmonary disease, viral hepatitis B, ischemic heart disease), osteonecrosis of the femoral head, and use of NsaiDs (non-steroidal anti-inflammatory drugs) at diagnosis of cOViD-19; at the diagnosis of acs associated with cOViD-19, respiratory distress, hypoxia (sa02 < 92%), creatininemia >18.5 mg/l, cRP >192 mg/l, lymphopenia; the therapeutic modalities associated with death were: transfusion of RBcs (packed red blood cells) and curative anticoagulation. this study shows that patients with comorbidities and/or chronic complications of sickle cell disease can develop severe forms of acs associated with cOViD 19, leading to death. Other factors linked to death, notably diagnostic and therapeutic, were also identified in the course of this study. Patients and methodsWe conducted a 36-month (January
